Malaysia
Search
Sign In
Change Password
Points
Sign Out
Top Medical News
DCH Auriga recently held their first Aesthetics and Suturing Workshop under the IMPACT continuing medical education series – a scientific platform that aims to cascade the latest updates on disease management and share best clinical practices among healthcare professionals in Singapore. Two experts on aesthetics and aesthetic surgery shared their insights on suturing techniques and current approaches for scar prevention and management.
Interleukin 17A (IL-17A) inhibitors show better efficacy than ustekinumab in achieving clearance in adults with moderate-to-severe plaque psoriasis, a recent study has shown. Additionally, IL-17A inhibitors are generally more effective than etanercept, adalimumab and apremilast.
Use of antitumour necrosis factor (anti-TNF) agents in patients with inflammatory bowel disease (IBD) appears to be associated with an increased likelihood of developing psoriasiform diseases, with the risk of palmoplantar pustulosis most pronounced in males and younger patients, according to a study.
Matching targeted therapy to genetic alterations in the tumour improved response rate and long-term survival in patients with advanced cancer who underwent molecular profiling compared with patients who were unmatched to therapy, highlighting the role of molecular testing in precision medicine, the IMPACT* study shows.
The newest version of the Atlas of Paediatric Diseases was officially launched at the recent Malaysian Society of Allergy and Immunology (MSAI) conference, held in Kuala Lumpur recently.
Pemphigus patients with high baseline antidesmoglein 1 (anti-DSG1) indices relapse earlier, highlighting the importance of following them closely for the initial 12 months after rituximab therapy, suggests a recent study, adding that a maintenance rituximab dose during the first 12 months after initial therapy may be needed.
JAK inhibitor tofacitinib appear to have therapeutic potential to halt hair loss in patients with alopaecia areata, a recent study has shown.
Special Reports
DCH Auriga recently held their first Aesthetics and Suturing Workshop under the IMPACT continuing medical education series – a scientific platform that aims to cascade the latest updates on disease management and share best clinical practices among healthcare professionals in Singapore. Two experts on aesthetics and aesthetic surgery shared their insights on suturing techniques and current approaches for scar prevention and management.
The prevalence of allergic diseases in the Asia-Pacific region is expected to rise over the next 20 years, driven by rapid economic development and urbanization. Allergic diseases have high socioeconomic impact by impairing productivity and quality of life, and the impact may be greater in Asia-Pacific than in Europe due to the presence and predominance of perennial allergens.
Eczema (atopic dermatitis) is a chronic inflammatory skin disease that
can present in many different forms. However, it is principally
characterized by dry skin, intense itching, and the presence of
inflammatory skin lesions. [J Eur Acad Dermatol Venereol
2016;30:604-618; N Engl J Med 2008;358:1483-1494; Lancet
2016;387:1109-1122]
At the 42nd Annual Dermatology Conference 2017 held recently in Kuala Lumpur, Professor Michael J. Cork spoke on the interaction between genetic and environmental factors as a primary event in the development of atopic dermatitis (AD) and highlighted the role of topical calcineurin inhibitors (TCIs) in the management of AD.
The prevalence of atopic dermatitis (AD) in industrialized countries has increased exponentially over the past three decades, currently affecting 15 to 30% of children and up to 10% of adults.1 At the recent official launch event of pimecrolimus (Elidel®, Meda Healthcare Sdn. Bhd.) held at Le Méridien Kuala Lumpur, Professor Thomas Luger provided insights on the pathophysiology of AD and the role of topical calcineurin inhibitors (TCIs) in the management of AD.
CANESTEN HC – Clotrimazole 1% w/w and hydrocortisone 1% w/w cream – Bayer
All patients with acne are potentially at risk of scarring. Professor Goh Chee Leok addresses this issue by focussing on preventing the development of scars in his talk at the 41st Annual Meeting of the Dermatological Society of Malaysia held in Kuching, Sarawak.
Conference Reports
Continued treatment with the anti-interleukin (IL)-23 monoclonal antibody guselkumab generated high efficacy response rates in patients with moderate-to-severe plaque psoriasis, according to findings from the ongoing phase III VOYAGE 2* trial presented at the 2018 American Academy of Dermatology Annual Meeting (AAD 2018) held in San Diego, California, US.
The approved psoriasis therapy ustekinumab also reduces aortic vascular inflammation, along with improved psoriasis severity, compared with placebo in patients with moderate-to-severe psoriasis, according to the VIP-U* study presented at the 2018 American Academy of Dermatology (AAD) Annual Meeting in San Diego, California, US.
The humanized IgG1 monoclonal antibody risankizumab cleared plaque psoriasis better than ustekinumab and placebo in two phase III head-to-head studies. Risankizumab also appeared to be superior to ustekinumab or placebo in many endpoints.
